VRPX (Virpax Pharmaceuticals) Total Inventories : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Virpax Pharmaceuticals Total Inventories?

Virpax Pharmaceuticals's total inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. Virpax Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Virpax Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-1.60.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Virpax Pharmaceuticals Total Inventories Historical Data

The historical data trend for Virpax Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virpax Pharmaceuticals Total Inventories Chart

Virpax Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

Virpax Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Virpax Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Virpax Pharmaceuticals (NAS:VRPX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Virpax Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

	Net-Net Working Capital Per Share (Q: Dec. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.513	+	0.75 * 0	+	0.5 * 0	-	2.469
-	0	-	0)	/	0.596
=	-1.60

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Virpax Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Virpax Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Virpax Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Virpax Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Virpax Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Virpax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virpax Pharmaceuticals Inc (NAS:VRPX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312

Website

https://www.virpaxpharma.com

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Executives

Sheila Mathias	officer: Chief Scientific Officer	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Vinay Shah	officer: Chief Financial Officer	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Barbara Ruskin	director	C/O VIRPAX PHARMACEUTICALS, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jerrold Sendrow	director	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Eric Floyd	director	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Anthony P. Mack	director, 10 percent owner, officer: Chief Executive Officer	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Michael F Dubin	director	C/O VIRPAX PHARMACEUTICALS, 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Gary S Jacob	director
Christopher Michael Chipman	officer: Chief Financial Officer	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Jeffrey Gudin	director, officer: Chief Medical Officer	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Thani Jambulingam	director	C/O VIRAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Gerald W Bruce	officer: EVP, Commercial Operations	NITROMED INC, 125 SPRING STREET, LEXINGTON MA 02421
Virpax Pharmaceuticals Llc	10 percent owner	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380